Multiple Myeloma Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI102693

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Multiple Myeloma - by Key Countries - 2024
2. Pipeline Analysis
3. Key Industry Developments
4. Regulatory Scenario, by Key Regions
5. Analysis Of Economic Burden of Multiple Myeloma Treatment
6. New Product Launches
7. Overview of Emerging Treatments for Multiple Myeloma
Global Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country
  1. U.S.
  2. Canada
Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. GCC Countries
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2017)
3. Competition Dashboard
4. Comparative Analysis – Major Players
5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  1. Takeda Pharmaceutical Company Limited
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  2. Novartis AG
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  3. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  4. Bristol Myers Squibb Company
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  5. Amgen Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  6. ONO PHARMACEUTICAL CO., LTD.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  7. Janssen Pharmaceuticals, Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  9. CELGENE CORPORATION (Bristol Myers Squibb Company)
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  10. AbbVie Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  11. Sanofi
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  12. Other Prominent Players
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
Strategic Recommendation

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Multiple Myeloma - by Key Countries - 2024
2. Pipeline Analysis
3. Key Industry Developments
4. Regulatory Scenario, by Key Regions
5. Analysis Of Economic Burden of Multiple Myeloma Treatment
6. New Product Launches
7. Overview of Emerging Treatments for Multiple Myeloma
Global Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country
  1. U.S.
  2. Canada
Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. GCC Countries
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2017)
3. Competition Dashboard
4. Comparative Analysis – Major Players
5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  1. Takeda Pharmaceutical Company Limited
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  2. Novartis AG
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  3. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  4. Bristol Myers Squibb Company
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  5. Amgen Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  6. ONO PHARMACEUTICAL CO., LTD.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  7. Janssen Pharmaceuticals, Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  9. CELGENE CORPORATION (Bristol Myers Squibb Company)
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  10. AbbVie Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  11. Sanofi
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  12. Other Prominent Players
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
Strategic Recommendation

Read Less

List of Figures

Figure 1: Global Multiple Myeloma Market Revenue Breakdown (US$ Bn, %) by Region, 2024 & 2032

Figure 2: Global Multiple Myeloma Market Value Share (%), by Drug Class, 2024 & 2032

Figure 3: Global Multiple Myeloma Market Forecast (US$ Bn), by Immunomodulators, 2019-2032

Figure 4: Global Multiple Myeloma Market Forecast (US$ Bn), by Proteasome Inhibitor, 2019-2032

Figure 5: Global Multiple Myeloma Market Forecast (US$ Bn), by Anti-CD38 Monoclonal Antibody, 2019-2032

Figure 6: Global Multiple Myeloma Market Forecast (US$ Bn), by Alkylating Agents, 2019-2032

Figure 7: Global Multiple Myeloma Market Forecast (US$ Bn), by Others, 2019-2032

Figure 8: Global Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 9: Global Multiple Myeloma Market Forecast (US$ Bn), by Hospital Pharmacies, 2019-2032

Figure 10: Global Multiple Myeloma Market Forecast (US$ Bn), by Retail Pharmacies & Drug Stores, 2019-2032

Figure 11: Global Multiple Myeloma Market Forecast (US$ Bn), by Online Pharmacies, 2019-2032

Figure 12: Global Multiple Myeloma Market Value (US$ Bn), by Region, 2024 & 2032

Figure 13: North America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2024 & 2032

Figure 14: North America Multiple Myeloma Market Value Share (%), by Drug Class, 2024

Figure 15: North America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2024 & 2032

Figure 16: North America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024

Figure 17: North America Multiple Myeloma Market Value (US$ Bn), By Country, 2024 & 2032

Figure 18: North America Multiple Myeloma Market Value Share (%), By Country, 2024

Figure 19: Europe Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2024 & 2032

Figure 20: Europe Multiple Myeloma Market Value Share (%), by Drug Class, 2024

Figure 21: Europe Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2024 & 2032

Figure 22: Europe Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024

Figure 23: Europe Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2024 & 2032

Figure 24: Europe Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2024

Figure 25: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2024 & 2032

Figure 26: Asia Pacific Multiple Myeloma Market Value Share (%), by Drug Class, 2024

Figure 27: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2024 & 2032

Figure 28: Asia Pacific Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024

Figure 29: Asia Pacific Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2024 & 2032

Figure 30: Asia Pacific Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2024

Figure 31: Latin America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2024 & 2032

Figure 32: Latin America Multiple Myeloma Market Value Share (%), by Drug Class, 2024

Figure 33: Latin America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2024 & 2032

Figure 34: Latin America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024

Figure 35: Latin America Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2024 & 2032

Figure 36: Latin America Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2024

Figure 37: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2024 & 2032

Figure 38: Middle East & Africa Multiple Myeloma Market Value Share (%), by Drug Class, 2024

Figure 39: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2024 & 2032

Figure 40: Middle East & Africa Multiple Myeloma Market Value Share (%), by Distribution Channel, 2024

Figure 41: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2024 & 2032

Figure 42: Middle East & Africa Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2024

Figure 43: Global Multiple Myeloma Market Share (%), By Company, 2024

List of Tables

Table 1: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019–2032

Table 2: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019–2032

Table 3: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Region, 2019-2032

Table 4: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019-2032

Table 5: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019-2032

Table 6: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country, 2019-2032

Table 7: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019-2032

Table 8: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019-2032

Table 9: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2019-2032

Table 10: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019-2032

Table 11: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019-2032

Table 12: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2019-2032

Table 13: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019-2032

Table 14: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019-2032

Table 15: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2019-2032

Table 16: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2019-2032

Table 17: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2019-2032

Table 18: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2019-2032

STUDY PERIOD: 2019-2032
BASE YEAR: 2024
HISTORICAL DATA: 2019-2023
NO OF PAGES: 110

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com